Overview

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy

Status:
Active, not recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of Tildrakizumab in moderate-to-severe plaque psoriasis participants who are non-responder to Dimethyl fumarate (DMF) at Week 16. The study consists of two parts. Part 1 will include the first 16 weeks of the Treatment Period and Part 2 will include the last 24 weeks of the Treatment Period.

Phase:

Phase 4

Details

Lead Sponsor:

Almirall, S.A.

Treatments:

Antibodies, Monoclonal
Dimethyl Fumarate